Results 201 to 210 of about 53,341 (352)

Prohibited Olympic Medalist with PIEZO1 VUS Who Claims Innocence. [PDF]

open access: yesInt J Mol Sci
Sonkodi B   +8 more
europepmc   +1 more source

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

open access: yesMolecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza   +3 more
wiley   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

open access: yesMolecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh   +5 more
wiley   +1 more source

Pericytes change function depending on glioblastoma vicinity: emphasis on immune regulation

open access: yesMolecular Oncology, EarlyView.
Pericytes alter their transcriptome depending on their proximity to the tumor core. In the tumor core, pericytes display a more active state with higher communication strength but with lower immune activation potential and a shift toward extracellular matrix production.
Carolina Buizza   +5 more
wiley   +1 more source

Single‐cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology

open access: yesMolecular Oncology, EarlyView.
Single‐cell transcriptomics of prostate cancer patient‐derived xenografts reveals distinct features of neuroendocrine (NE) subtypes. Tumours with focal NE differentiation (NED) share transcriptional programmes with adenocarcinoma, differing from large and small cell neuroendocrine prostate cancer (NEPC). Our work defines the molecular landscape of NEPC,
Rosalia Quezada Urban   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy